A New Receptor-Binding Role For MicroRNAs In Cancer
This article was originally published in Start Up
A research team has identified a new role for microRNAs, the small pieces of noncoding RNA that can influence gene expression. They show that miRNAs generated in solid tumors will infiltrate into nearby cells, binding with a toll-like receptor and promoting chronic inflammation – a hallmark of the spread of many solid tumors. The researchers believe they will be able to identify a drug target and small molecules that can block the miRNA-TLR binding interaction, offering up a novel treatment strategy for cancer and possibly other diseases characterized by chronic inflammation.
You may also be interested in...
A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.
A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.
A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.